Tobias Schatton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7844634/publications.pdf Version: 2024-02-01



TOBIAS SCHATTON

#	Article	IF	CITATIONS
1	PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncolmmunology, 2018, 7, e1435226.	2.1	36
2	Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity. JCl Insight, 2018, 3, .	2.3	48
3	Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. Annals of Surgical Oncology, 2017, 24, 2698-2706.	0.7	24
4	T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Laboratory Investigation, 2017, 97, 669-697.	1.7	167
5	ABCB5-Targeted Chemoresistance Reversal Inhibits Merkel Cell Carcinoma Growth. Journal of Investigative Dermatology, 2016, 136, 838-846.	0.3	19
6	Homing in on the Sweet Side of Immune Checkpoint Biology. Immunity, 2016, 44, 1083-1085.	6.6	4
7	Tumour-infiltrating lymphocytes in melanoma prognosis andÂcancerÂimmunotherapy. Pathology, 2016, 48, 177-187.	0.3	210
8	ABCB5 Identifies Immunoregulatory Dermal Cells. Cell Reports, 2015, 12, 1564-1574.	2.9	51
9	Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. Journal of Investigative Dermatology, 2015, 135, 2475-2483.	0.3	51
10	Effects of Malignant Melanoma Initiating Cells on T-Cell Activation. Methods in Molecular Biology, 2015, , 1.	0.4	1
11	Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential. Journal of Investigative Dermatology, 2015, 135, 1849-1862.	0.3	29
12	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell, 2015, 162, 1242-1256.	13.5	507
13	Interleukin-10+ Regulatory B Cells Arise Within Antigen-Experienced CD40+ B Cells to Maintain Tolerance to Islet Autoantigens. Diabetes, 2015, 64, 158-171.	0.3	80
14	Merkel cell carcinoma expresses vasculogenic mimicry: demonstration in patients and experimental manipulation in xenografts. Laboratory Investigation, 2014, 94, 1092-1102.	1.7	17
15	Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. Laboratory Investigation, 2014, 94, 13-30.	1.7	63
16	Nestin depletion induces melanoma matrix metalloproteinases and invasion. Laboratory Investigation, 2014, 94, 1382-1395.	1.7	12
17	ABCB5 Maintains Melanoma-Initiating Cells through a Proinflammatory Cytokine Signaling Circuit. Cancer Research, 2014, 74, 4196-4207.	0.4	118
18	Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis. Methods in Molecular Biology, 2014, 1102, 287-324.	0.4	78

TOBIAS SCHATTON

#	Article	IF	CITATIONS
19	Genetically determined ABCB5 functionality correlates with pigmentation phenotype and melanoma risk. Biochemical and Biophysical Research Communications, 2013, 436, 536-542.	1.0	13
20	Tumor Dormancy and Cancer Stem Cells: Two Sides of the Same Coin?. Advances in Experimental Medicine and Biology, 2013, 734, 145-179.	0.8	108
21	Expression of MDRâ€transporter, ABCB5, in Merkel cell carcinoma. FASEB Journal, 2013, 27, 1087.8.	0.2	Ο
22	Metabolic Inhibition of Galectin-1-Binding Carbohydrates Accentuates Antitumor Immunity. Journal of Investigative Dermatology, 2012, 132, 410-420.	0.3	54
23	Loss of 5-Hydroxymethylcytosine Is an Epigenetic Hallmark of Melanoma. Cell, 2012, 150, 1135-1146.	13.5	688
24	Immunomodulatory Functions of Cancer Stem Cells. , 2012, , 301-332.		0
25	Colorectal Cancer Stem Cells: Biology and Therapeutic Implications. Current Colorectal Cancer Reports, 2011, 7, 128-135.	1.0	37
26	ABCB5 Identifies a Therapy-Refractory Tumor Cell Population in Colorectal Cancer Patients. Cancer Research, 2011, 71, 5307-5316.	0.4	121
27	VEGFR-1 Expressed by Malignant Melanoma-Initiating Cells Is Required for Tumor Growth. Cancer Research, 2011, 71, 1474-1485.	0.4	142
28	The Pro-Apoptotic Protein Bim Is a MicroRNA Target in Kidney Progenitors. Journal of the American Society of Nephrology: JASN, 2011, 22, 1053-1063.	3.0	92
29	Melanoma Stem Cells. , 2011, , 255-279.		0
30	The therapeutic promise of the cancer stem cell concept. Journal of Clinical Investigation, 2010, 120, 41-50.	3.9	573
31	The In Vitro Spheroid Melanoma Cell Culture Assay: Cues on Tumor Initiation?. Journal of Investigative Dermatology, 2010, 130, 1769-1771.	0.3	34
32	Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells. Cancer Research, 2010, 70, 697-708.	0.4	256
33	A novel in vivo regulatory role of P-glycoprotein in alloimmunity. Biochemical and Biophysical Research Communications, 2010, 394, 646-652.	1.0	6
34	Isolation of tumorigenic circulating melanoma cells. Biochemical and Biophysical Research Communications, 2010, 402, 711-717.	1.0	57
35	Identification and targeting of cancer stem cells. BioEssays, 2009, 31, 1038-1049.	1.2	157
36	Antitumor Immunity and Cancer Stem Cells. Annals of the New York Academy of Sciences, 2009, 1176, 154-169.	1.8	145

TOBIAS SCHATTON

#	Article	IF	CITATIONS
37	Solid Tumor Stem Cells – Implications for Cancer Therapy. , 2009, , 527-543.		1
38	Cancer stem cells and human malignant melanoma. Pigment Cell and Melanoma Research, 2008, 21, 39-55.	1.5	181
39	Identification of cells initiating human melanomas. Nature, 2008, 451, 345-349.	13.7	1,327
40	Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist Gremlin. Journal of Cell Biology, 2006, 175, 99-110.	2.3	61
41	ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma. Cancer Research, 2005, 65, 4320-4333.	0.4	537